Table 1 Baseline characteristics of study patients

Parameter

n = 215

n = 102

n = 48

n = 42

n = 23

 Gender, m/f (%)

185/30 (86.0/14.0)

85/17 (83.3/16.7)

42/6 (87.5/12.5)

36/6 (85.7/14.3)

22/1 (95.7/4.3)

 Age, median (min.- max.)

69 (33 – 87)

70 (41 -87)

64 (33 – 85)

68 (46 – 85)

70 (50 -87)

 ECOG

  0

149 (69.3)

65 (63.7)

35 (72.9)

29 (69.1)

20 (87.0)

  1

31 (14.4)

14 (13.7)

6 (12.5)

8 (19.0)

3 (13.0)

  2

35 (16.3)

23 (22.6)

7 (14.6)

5 (11.9)

0

Viral (%)

68 (31.6)

29 (28.4)

16 (33.3)

16 (38.1)

7 (30.4)

 HBV (%)^|

41 (60.3)

18 (62.1)

7 (43.8)

12 (75.0)

4 (57.1)

 HCV (%)^|

27 (39.7)

11 (37.9)

9 (56.2)

4 (25.0)

3 (42.9)

Non-viral (%)

147 (68.4)

73 (71.6)

32 (66.7)

26 (61.9)

16 (69.6)

 Alcohol (%)^|

82 (55.7)

42 (57.5)

18 (56.3)

14 (53.8)

8 (50.0)

 NAFLD (%)^|

21 (14.4)

12 (16.4)

1 (3.1)

6 (23.1)

2 (12.4)

 cryptogenic (%)^|

35 (23.8)

16 (21.9)

9 (28.1)

6 (23.1)

4 (25.0)

 hemochromatosis (%)^|

8 (5.4)

3 (4.1)

4 (12.5)

-

1 (6.3)

 autoimmune (%)^|

1 (0,7)

-

-

-

1 (6.3)

Score, median

5 (5-14)

6 (5-14)

5 (5-9)

5 (5-9)

5 (5-9)

 (min.-max.)

18 (78.3)

 Child A

146 (67.9)

57 (55.8)

38 (79.2)

33 (78.6)

5 (21.7)

 Child B

57 (26.5)

33 (32.4)

10 (20.8)

9 (21.4)

0

 Child C

12 (5.6)

12 (11.8)

0

0

ALBI score^##median (min.- max.)

−2.11 (−4.69 – −0.32)

−1.79 (− 3.25 – −0.32)

−2.36 (−3.36 – −0.85)

−2.19 (−4.69 – −0.76)

−2.23 (−3.32- - 1.13)

ALBI grade^##(%)

ALBI 1

53 (24.7)

16 (15.7)

17 (35.4)

11 (26.2)

9 (39.1)

 ALBI 2

122 (56.7)

54 (52.9)

29 (60.4)

28 (66.7)

11 (47.9)

 ALBI 3

40 (18.6)

32 (31.4)

2 (4.2)

3 (7.1)

3 (13.0)

Intrahepatic HCC: oligonodular vs. multifocal (%)

51 / 149 (26.6/73.4)

22 /80 (21.6/78.4)

8 /40 (16.7/83.3)

17 / 25 (40.5/59.5)

7/16 (30.4/69.6)

Segmental portal vein thrombosis (%)

36 (17.4)

19 (18.6)

5 (10.4)

7 (16.7)

5 (21.7)

BCLC (%)

 C

183 (85.1)

74 (72.5)

44 (91.7)

42 (100)

23 (100)

 D

32 (14.9)

28 (27.5)

4 (8.3)

0

0

Largest tumor diameter [cm], median (min.-max.)

5.2 (1 – 18)

5.8 (1 – 17

4.4 (1 – 17)

5.3 (1- 17)

7 (2- 18)

Largest tumor size >7 cm (%)

66 (30.7)

34 (33.3)

9 (18.8)

12 (28.6)

11 (47.8)

Location of metastases

 Lung

65 (30.1)

38 (37.3)

11 (22.9)

9 (21.4)

7 (30.4)

 Bone

24 (11.2)

11 (10.8)

5 (10.4)

3 (7.1)

5 (21.7)

 Lymph nodes

42 (19.5)

14 (13.7)

8 (16.7)

17 (40.5)

3 (13.1)

 Peritoneum

12 (5.6)

5 (4.9)

3 (6.3)

3 (7.1)

1 (4.4)

 Adrenal gland

4 (1.9)

3 (2.9)

0

1 (2.4)

0

 Others

18 (8.4)

10 (9.8)

2 (4.2)

6 (14.3)

0

 Multiple sites^*

50 (23.3)

21 (20.6)

19 (39.5)

3 (7.2)

7 (30.4)

 White blood count [10⁶/μl]

6. 7 (2.1 – 34.4)

6,4 (2.1 – 28.0)

6.8 (2.6 – 23.0)

6.6 (2.4 – 34.4)

6.8 (2.6 – 14.4)

 Platelets [10⁶/μl]

157 (9 -702)

150 (9 -702)

201 (29 – 363)

145 (56 – 480)

161 (51 -401)

 Hemoglobin [g/dl]

12.3 (6.8 – 19.1)

11.9 (6.8 – 16.4)

12.9 (7.8 – 19.1)

13.1 (8.9 – 17.3)

12.6 (7.8 -14.9)

 INR

1.13 (0.7 – 10.0)

1.17 (0.7 – 10.0)

1.12 (0.8 – 2.6)

1.10 (0.8 – 3.4)

1.01 (0.8 – 3.2)

 Creatinine [mg/dl]

0.9 (0.4 – 7.4)

0.9 (0.4 – 5.5)

0.9 (0.5 – 7.4)

0.9 (0.4 – 2.1)

0.9 (0.6 – 1.3)

 AST [U/l]

75 (12 – 674)

96 (18 – 674)

75 (25 – 450)

56 (12 – 252)

65 (20 -472)

 ALT [U/l]

47 (8 - 640)

48 (13 -640)

49 (16 – 205)

45 (8 – 234)

46 (15 – 253)

 Bilirubin [mg/dl]

1.0 (0.3 – 30.9)

1.5 (0.3 -30.9)

0.9 (0.3 – 6.8)

0.9 (0.4 – 14.9)

0.8 (0.4 – 2.5)

 Albumin [g/dl]

3.5 (2.0 – 6.4)

3.3 2.0 – 4.7)

3.7 (2.4 – 4.6)

3.5 (2.5 – 6.4)

3.7 (2.4 – 4.6)

 AFP [ng/ml]

222.0 (0.6 – 502,900.0^**)

303.1 1.1 – 502,900.0)

174.6 (1.1 – 60,500.0^**)

71.4 (0.6 – 60,500.0)

174.0 (1.5 – 60,500.0)

AFP > 400 ng/ml (%)

93 (43.3)

49 (48.0)

20 (41.7)

16 (38.1)

8 (34.8)